【华东医药：控股子公司注射用DR30206临床试验获批】华东医药公告称，公司控股子公司浙江道尔生物科技有限公司收到国家药监局核准签发的《药物临床试验批准通知书》，其申报的注射用DR30206临床试验申请获得批准。该产品为1类治疗用生物制品，是靶向PD-L1、VEGF和TGF-β的抗体融合蛋白，本次获批适应症为作为巩固治疗，拟用于同步/序贯放化疗后未进展的、局部晚期/不可切除的非小细胞肺癌患者。该产品尚需完成后续临床试验并经审评审批通过后方可上市，本次进展对公司近期业绩不会产生重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.